Company Overview and News

2
HGV / Hilton Grand Vacations Inc. FORM 8-K (Current Report)

2018-09-19 sec.gov - 2
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HGV

1
Playa Hotels & Resorts and Hilton Announce Strategic Alliance and Future Conversion of Two Initial All-inclusive Resorts

2018-09-17 globenewswire
FAIRFAX, Va. and MCLEAN, Va., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Playa Hotels & Resorts N.V. (NASDAQ: PLYA) and Hilton (NYSE: HLT) today announced plans to leverage Playa Hotels & Resorts’ industry-leading, all-inclusive expertise with Hilton’s global portfolio of brands, and over 78 million participating members in Hilton Honors, Hilton’s award-winning loyalty program, to accelerate the growth of Hilton’s all-inclusive resorts.
HGV PLYA HLT

 
What Is Happening With Hilton Grand Vacations?

2018-09-04 seekingalpha
Hilton Grand Vacations stock has been down 30% in the past 6 months, despite recent results that have been nowhere near disastrous.
VAC CUKPF HGV CCL CCL CUK WYND

 
Hilton Offers Metropolitan Washington Hotel Package for Fall

2018-08-22 accesswire
WASHINGTON, DC / ACCESSWIRE / August 22, 2018 / Travelers interested in touring the nation's capital this fall can book the Capital Adventure Package, available at 59 area Hilton hotels, and complete with deals on the best things to do in and around Washington, DC. This travel package is available at participating hotels throughout the DC area with something for everyone, including the air travel-friendly Hilton Crystal City, the shopping district-adjacent Hilton Alexandria Mark Center, the neighborly characteristics surrounding Washington Hilton, or the boutique, stylish Canopy Bethesda North.
HGV

 
HGV / Hilton Grand Vacations Inc. FORM 8-K (Current Report)

2018-08-10 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 HGV

 
HGV / Hilton Grand Vacations Inc. FORM 8-K (Current Report)

2018-08-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 HGV

 
HGV / Hilton Grand Vacations Inc. 10-Q -2018 Q2 (Quarterly Report)

2018-08-02 sec.gov
hgv-10q_20180630.htm UNITED STATES
HGV

 
HGV / Hilton Grand Vacations Inc. 8-K/A (Current Report)

2018-08-02 sec.gov
hgv-8ka_20180801.htm
HGV

13
Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS

2018-08-01 zacks - 2
Chicago, IL – August 1, 2018 - Stocks in this week’s article are Hilton Grand Vacations Inc. (HGV - Free Report) , Fastenal Company (FAST - Free Report) , Catalyst Biosciences Inc. (CBIO - Free Report) , OpGen Inc. (OPGN - Free Report) and ConforMIS Inc. (CFMS - Free Report) .
CBIO OPGNW HGV OPGN CFMS

13
5 Top-Ranked Stocks to Benefit From Rising P/E Investing

2018-07-31 investorplace - 2
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.
CBIO HGV FAST OPGN CFMS

6
GoPro (GPRO) to Report Q2 Earnings: What's in the Cards?

2018-07-31 zacks
GoPro, Inc. (GPRO - Free Report) is scheduled to report second-quarter 2018 financial results after the closing bell on Aug 2. In the last reported quarter, the company delivered a positive earnings surprise of 15%. Let’s see how things are shaping up for this announcement. Factors to Consider During the second quarter, GoPro achieved the milestone of more than 30 million HERO cameras sale since the debut of its first HD model in November 2009.
GPRO FCN HGV UFS SFUN UTX NMIH

11
Factors Setting the Tone for MGM Resorts (MGM) Q2 Earnings

2018-07-31 zacks
MGM Resorts International (MGM - Free Report) is scheduled to report second-quarter 2018 results on Aug 2, before market open. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 9.7%.
CWH MGM HGV CZR GPN RRR

19
5 Top-Ranked Stocks to Benefit From Rising P/E Investing

2018-07-31 zacks
Generally, investors love stocks with a low price-to-earnings (P/E) ratio. The idea is that the lower the P/E, the higher will be the value of the stock. The simple logic that a stock’s current market price does not validate (is not equivalent to) its higher earnings and therefore has room to run justifies investors’ inclination toward low P/E stocks.
CBIO OPGNW CWH AMKR HGV OPGN EMES CFMS

5
Factors Setting the Tone for Wynn Resorts (WYNN) Q2 Earnings

2018-07-30 zacks
Wynn Resorts, Limited (WYNN - Free Report) is scheduled to release second-quarter 2018 results on Aug 1, after market close. The company’s earnings have surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average beat of 9.9%.
ALGN HGV WYNN CZR LVS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 43283X105